Biocept Analysis
Biocept holds a debt-to-equity ratio of 0.331. With a high degree of financial leverage come high-interest payments, which usually reduce Biocept's Earnings Per Share (EPS).
Asset vs Debt
Equity vs Debt
Biocept's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Biocept's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Biocept Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Biocept's stakeholders.
For most companies, including Biocept, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Biocept, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Biocept's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Given that Biocept's debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Biocept is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Biocept to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Biocept is said to be less leveraged. If creditors hold a majority of Biocept's assets, the Company is said to be highly leveraged.
Biocept is undervalued with Real Value of 0.0 and Hype Value of 0.0. The main objective of Biocept delisted stock analysis is to determine its intrinsic value, which is an estimate of what Biocept is worth, separate from its market price. There are two main types of Biocept's stock analysis: fundamental analysis and technical analysis.
The Biocept stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Biocept's ongoing operational relationships across important fundamental and technical indicators.
Biocept |
Biocept Stock Analysis Notes
The company has price-to-book (P/B) ratio of 0.37. Some equities with similar Price to Book (P/B) outperform the market in the long run. Biocept recorded a loss per share of 48.17. The entity last dividend was issued on the 8th of September 2020. The firm had 1:30 split on the 17th of May 2023. Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California. Biocept operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 177 people. For more info on Biocept please contact Samuel Riccitelli at 858 320 8200 or go to https://biocept.com.Biocept Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more delisted stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Biocept's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Biocept or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| Biocept is not yet fully synchronised with the market data | |
| Biocept has some characteristics of a very speculative penny stock | |
| Biocept has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 25.86 M. Net Loss for the year was (32.09 M) with loss before overhead, payroll, taxes, and interest of (2.58 M). | |
| Biocept currently holds about 27.57 M in cash with (13.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.63. |
Biocept Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Biocept previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of November 2023 Upcoming Quarterly Report | View | |
| 30th of September 2023 Next Fiscal Quarter End | View |
Biocept Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 1.14 M.Biocept Outstanding Bonds
Biocept issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Biocept uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Biocept bonds can be classified according to their maturity, which is the date when Biocept has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Biocept Debt to Cash Allocation
As Biocept follows its natural business cycle, the capital allocation decisions will not magically go away. Biocept's decision-makers have to determine if most of the cash flows will be poured back into or reinvested in the business, reserved for other projects beyond operational needs, or paid back to stakeholders and investors.
Biocept currently holds 12.11 M in liabilities with Debt to Equity (D/E) ratio of 0.33, which is about average as compared to similar companies. Biocept has a current ratio of 3.31, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Biocept's use of debt, we should always consider it together with its cash and equity.Biocept Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Biocept's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Biocept, which in turn will lower the firm's financial flexibility.Biocept Corporate Bonds Issued
Most Biocept bonds can be classified according to their maturity, which is the date when Biocept has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Biocept to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Instant Ratings Now
Instant RatingsDetermine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |
| All Next | Launch Module |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Other Consideration for investing in Biocept Stock
If you are still planning to invest in Biocept check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Biocept's history and understand the potential risks before investing.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |